Remgro Limited Overview
Remgro is the Rupert family-controlled investment holding company that houses the family's South African industrial, financial and infrastructure interests. It is the domestic sibling of Richemont (luxury) and Reinet (international investments). Its portfolio is concentrated in assets that are hard to replicate in South African public markets. These include full ownership of Mediclinic Southern Africa (from 1 July 2026), a 57% controlling stake in the CIVH fibre group (Vumatel, Dark Fibre Africa), now co-owned at the Maziv level with Vodacom, and roughly 30% of OUTsurance Group. Food and consumer holdings include Rainbow, RCL Foods, Siqalo Foods and Heineken Beverages; industrial joint ventures include Air Products SA and TotalEnergies SA. Since 2020, a "simplify, optimise, focus" strategy has moved the portfolio away from listed holdings that investors can buy directly. Remgro exited FirstRand and British American Tobacco (BAT), unbundled Grindrod and eMedia, and took Mediclinic private. Remgro enters FY2027 with record headline earnings, roughly R20bn of net cash at the centre, and a persistent 30–45% discount to INAV.
What Remgro does
| Pillar (company reporting platform) | Principal current holdings (status Oct 2026) |
|---|---|
| Healthcare | Mediclinic Southern Africa (100% from 1 Jul 2026). Joint 50/50 holding with MSC in the Middle East business (EHH Group) and in the Spire Healthcare minority stake |
| Consumer products | RCL Foods (c.79.6%), Rainbow Chicken (c.80.0%), Siqalo Foods (100%), Heineken Beverages (c.18.8% effective), Capevin |
| Financial services | OUTsurance Group (c.30.6%), Business Partners, minority stakes in Discovery (c.7.8% per Profile) and Momentum |
| Infrastructure | CIVH (57.0%), which owns 70% of Maziv (Vumatel, Dark Fibre Africa, interest in Herotel) alongside Vodacom's 30%; SEACOM |
| Industrial | Air Products South Africa (50%), TotalEnergies Marketing South Africa (24.9%), Wispeco (100%) |
| Media & sport | eMedia unbundled September 2025. Sport and social-impact interests remain (e.g., Blue Bulls, Stellenbosch FC, Stellenbosch Academy of Sport) |
| Diversified investment vehicles | Kagiso Tiso Holdings (43.5%) and other funds/vehicles with a focus on South Africa and China (per Old Mutual Aperture research, Mar 2026) |
| Social impact | Sport and community investments |
| Central treasury | Cash at the centre: R20.4bn at 30 Jun 2026, R22.5bn post year-end (Remgro FY2026 results presentation, per Quartr) |
Remgro is a diversified, long-horizon investment holding company. It does not run a single operating business. Instead it acquires, controls or co-controls, and actively manages stakes in South African and selected international businesses.
The company's own description in its Profile's Handbook entry and annual reporting covers four points:
-
The portfolio has evolved substantially since its 1940s founding.
-
It now spans nine reporting pillars.
-
Its interests are mainly in healthcare, consumer products, financial services, infrastructure, industrial and media.
-
The most significant investments contribute about 88% of INAV after tax. At the last Profile disclosure, these were Mediclinic, OUTsurance Group, CIVH, Heineken Beverages, RCL Foods, Rainbow, FirstRand, Discovery, Siqalo Foods, Air Products, TotalEnergies and Kagiso Tiso Holdings (KTH).
FirstRand has since been fully sold and eMedia unbundled. The pillar structure therefore now consists of the following:
Stake percentages are the latest available in Profile's Stock Exchange Handbook (2026 Issue 1, reflecting 30 June 2025 disclosures) and press coverage. Stakes may have changed since; FY2026 IAR percentages were not available this cycle.
Business and revenue model
| Revenue type | Share of value creation | Notes |
|---|---|---|
| Product revenue (consolidated subsidiaries) | ~100% of IFRS revenue | Sold through FMCG retail/wholesale channels (RCL, Rainbow, Siqalo) and industrial/construction channels (Wispeco) |
| Service revenue (look-through) | Large share of INAV | Hospitals (Mediclinic), insurance (OUTsurance), wholesale fibre (Maziv), industrial gases (Air Products) |
| Subscription/annuity (look-through) | Material | Insurance premiums, fibre access lines, gas supply contracts |
| Licensing | Not material | — |
Remgro's "revenue" in the economic sense has four layers:
-
Dividends from investees. Sustainable dividends of R2.428bn in H1 FY2026 (+34%), excluding a once-off CIVH pre-implementation dividend (Business Day, 25 Mar 2026).
-
Interest income on central cash. This rose in FY2026 on the back of FirstRand sale proceeds.
-
Realisations. Disposals (FirstRand R8.47bn; BAT R1.21bn) and corporate-action distributions (CIVH pre-implementation dividend).
-
Consolidated product revenue from controlled subsidiaries. Food, poultry, edible oils and spreads, aluminium extrusions and Scotch whisky (R51.0bn in FY2026).
Mix characterisation (independent).
Value chain position. Remgro is a capital provider and active owner. It sits above its operating companies and provides capital allocation, board control or joint control, deal-making (e.g., Maziv–Vodacom, Mediclinic restructuring), executive appointments and central services.
Customer types and end-markets (look-through).
-
South African consumers: food, poultry, spreads, beer and spirits, personal and vehicle insurance, fibre-to-the-home.
-
Patients and medical schemes: private hospitals.
-
Telecoms operators and ISPs: wholesale open-access fibre.
-
Industrial customers: oxygen, nitrogen, argon, hydrogen and CO₂.
-
Fuel retail and commercial customers: TotalEnergies.
-
Construction and engineering: aluminium extrusions.
Independent characterisation. Remgro is best understood as a South Africa-centric, family-controlled permanent-capital vehicle. It is moving from a listed-share "fund of stakes" toward an unlisted, control-oriented portfolio. According to CEO commentary reported from the 2025 Integrated Annual Report, about 77% of the portfolio was JSE-listed in 2020. The thesis is to replace exposure investors can replicate with assets accessible only through Remgro. The FY2026 transactions (FirstRand exit, Mediclinic SA full ownership, Maziv co-control with Vodacom) largely complete that pivot.
Strategy
Stated strategy (paraphrased from company communications)
-
"Simplify, optimise and focus" (adopted around 2020). Narrow the portfolio to fewer, larger and more controllable assets, and remove listed stakes that investors can hold directly. By September 2025 the board stated that a more focused investment thesis was beginning to emerge from the results (IOL, Sep 2025).
-
Shift to private, control or co-control assets. About 77% of the portfolio was JSE-listed in 2020. Each disposal of listed exposure (FirstRand, BAT, eMedia, Grindrod) and each privatisation (Mediclinic, MCSA) moves toward "assets only available through Remgro" (africa.com, citing the 2025 Annual Report).
-
Active partnership and ownership. Remgro pairs with strategic partners (MSC in healthcare, Vodacom in fibre, Heineken in beverages, Air Products in gases) and intervenes in performance (e.g., the RCL restructure).
-
Disciplined capital allocation. Cash at the centre is treated as "strategic cash resources" managed under a capital allocation framework (Remgro SENS, Mar 2026). The ordinary dividend is set at 1.5x adjusted FCF cover, with special dividends from realisations (200c in FY2025 linked to BAT; 550c in FY2026).
-
Next phase: value unlock and compounding (FY2026 onward). Management states that portfolio transformation is substantially complete. The focus now moves to converting the reshaped portfolio into measurable value creation (Business Day, Sep 2026; Quartr). AI is cited as a lever for executing strategy across the portfolio.
Strategic initiatives register (last 24 months)
| Initiative | Date | Description | Status |
|---|---|---|---|
| Vodacom/Maziv co-control | Implemented 1 Dec 2025 | Fibre consolidation with a strategic telco partner | Completed |
| Mediclinic restructuring | Agreed 30 Mar 2026; implemented 1 Jul 2026 | Full ownership of MCSA; exit from Hirslanden | Completed |
| FirstRand exit | Feb–Apr 2026 | Disposal of non-core listed bank stake (R8.47bn) | Completed |
| BAT exit | FY2025–Sep 2025 | Disposal of residual tobacco stake | Completed |
| eMedia unbundling | 29 Sep 2025 | Distribution of the c.35% stake to shareholders | Completed |
| Capital Markets Day | 2,025 | Articulation of the private-asset, active-management model | Completed |
| Special dividends | Sep 2025; Sep 2026 | Return of realisation proceeds | Ex-date for the FY2026 special dividend: 21 Oct 2026 |
| Board renewal | 2,025 | 12-year independence rule; new Deputy Chair; Ramon appointment | Ongoing |
| RCL Foods strategic options | Speculative | Market speculation about a minority buyout, sugar separation or a merger with Siqalo (Financial Mail, Mar 2026) | Unconfirmed — not announced by Remgro |
| AI enablement across portfolio | FY2026 results | Stated management priority | Early stage; no quantified targets disclosed |
Medium-term targets / guidance
Dividend policy: 1.5x adjusted free cash flow cover (maintained at FY2026).
-
No explicit HE, INAV growth or discount-to-INAV targets were disclosed in the sources reviewed.
-
Mediclinic, OUTsurance and other investees provide their own guidance; it is not aggregated by Remgro.
Products & Services
Because Remgro's "products" are its investee businesses, this section catalogues each investee, its offerings and named brands. Pricing models are generally not disclosed at Remgro level.
Healthcare
| Metric (USD Mn unless %) | FY Mar 2026 |
|---|---|
| Adjusted revenue | 5,356 |
| Adjusted revenue growth % | 11 |
| Adjusted EBITDA | 842 |
| Adjusted EBITDA growth % | 14 |
| Adjusted EBITDA margin % | 15.7 |
| Adjusted earnings | 345 |
| Adjusted earnings growth % | 45 |
| Statutory net loss | -733 |
| Impairments (restructuring-related) | 555 |
| Impairments (Swiss PPE and intangibles, before tax) | 689 |
Mediclinic Southern Africa (MCSA) — 100% owned from 1 July 2026
Description: private acute-care hospital and day-case network.
Footprint: around 50 private hospitals across South Africa and Namibia (BusinessTech, Sep 2026). Namibian hospitals include Windhoek, Swakopmund and Otjiwarongo (The Namibian, 2023).
Acquisition price: $947m (about R15.31bn) under the restructuring with MSC's IHL.
Performance (six months to 30 Sep 2025): - Revenue +8%, driven by volume growth and mix.
-
EBITDA margin up 70bp to 18.5%.
-
Occupancy flat.
Target customers: medical-scheme members and private-pay patients.
Pricing model: tariffs negotiated with medical schemes.
Mediclinic Middle East (EHH Group) — jointly held 50/50 with IHL
Description: hospitals and clinics in the UAE (Dubai and Abu Dhabi).
Performance (H1 to Sep 2025): revenue +11% on strong admissions; EBITDA margin 16.9% (+270bp).
Risk: the 2026 Middle East conflict complicated the operating environment.
Spire Healthcare (UK) minority stake — jointly held
- Mediclinic historically held about 29.9% of Spire.
Hirslanden (Switzerland) — exited 1 July 2026
-
Transferred 100% to IHL for $1,077m.
-
Remgro received a $130m cash equalisation distribution.
-
Before the exit, Hirslanden revenue was flat in H1 FY2026, with EBITDA margin +170bp.
-
Large impairments were taken in FY2026.
Combined Mediclinic Holdings, year to 31 March 2026 (voluntary summary published by Remgro, 29 May 2026):
Source: FilingReader summary of Remgro SENS (29 May 2026). The prior year's Swiss impairments were $279m.
Consumer products
| Division | Offerings | Named brands (public brand portfolio; not re-verified individually) |
|---|---|---|
| Groceries | Spreads, condiments, rusks, pet food, beverages | Nola, Yum Yum, Ouma, Bobtail, Mister Sweet |
| Baking | Bread and buns | Sunbake |
| Sugar | Irrigated cane sugar production (Selati), refined and brown sugar | Selati |
RCL Foods (c.79.6%) — JSE-listed
Groceries scale: RCL's groceries business has revenue of about R5.5bn (Financial Mail, Mar 2026).
Sugar division: this was the largest EBITDA contributor in H1 FY2025 (R750m). In H1 FY2026 Selati's profit fell 49% as margins halved under a flood of cheap imports (Financial Mail, Mar 2026).
Portfolio history: Vector Logistics was sold (Aug 2023, R1.25bn) and Rainbow unbundled (Jun 2024).
Pricing model: FMCG wholesale and retail.
Rainbow Chicken (c.80.0%) — JSE-listed since June 2024
Description: integrated poultry producer (broiler chicken, processed chicken) plus the Epol animal feed business.
FY2025 revenue: R15,838m.
H1 FY2026 performance: headline earnings +109–110% on 11% revenue growth, lower feed input costs and a stronger rand.
Contribution to Remgro FY2026 HE: +R610m.
Siqalo Foods (100%)
Description: edible fats, spreads and oils.
Financials: FY2025 revenue R3,715m. H1 FY2026 headline earnings −7% on volumes −2.7%, with stable margins after early-year price increases.
Valuation: Remgro valued Siqalo at R6.1bn (Financial Mail, Mar 2025).
Heineken Beverages Holdings (c.18.8% effective)
Description: Southern African beer, cider, spirits and wine business, majority-owned by Heineken.
Recovery: returned to profitability in FY2025 (+R406m swing). Further +R161m in FY2026, with strong beer momentum and margin expansion.
Capevin
-
Holds the former Distell remaining assets outside Heineken Beverages, including the Scotch whisky business.
-
FY2025 revenue R1,923m (FY2024: R2,659m).
Financial services
OUTsurance Group (c.30.6%) — JSE-listed
Description: direct short-term (non-life) insurance in South Africa, Youi in Australia, and international expansion. Also offers life insurance.
H1 FY2026: normalised earnings +12.6%, with SA strength partly offset by higher Youi claims.
FY2026 contribution change: +R332m to Remgro HE.
Business Partners
Description: specialist SME investment company providing finance, mentorship and property management services to small and medium enterprises.
Minority listed stakes
-
Discovery (c.7.8% per Profile 2026) and Momentum Group (percentage not disclosed in the sources reviewed).
-
FirstRand: fully exited April 2026.
Infrastructure
| Asset | Offering | Notes |
|---|---|---|
| Vumatel | Open-access fibre-to-the-home (FTTH) | H1 FY2026 revenue +15.4% |
| Dark Fibre Africa (DFA) | Metro and long-distance open-access fibre, business and transmission backhaul | H1 FY2026 revenue +3.6% |
| Vodacom fibre assets contributed | FTTH, FTTB and B2B transmission infrastructure | Valued at R4.9bn on contribution |
| Herotel | Regional/rural fibre and fixed-wireless ISP; Maziv holds about 49.9% | Vodacom paid about R0.6bn for its look-through share |
CIVH (57.0%), which owns 70% of Maziv (30% held by Vodacom since 1 Dec 2025)
Pricing model: wholesale access fees to ISPs and operators; annuity-type revenue.
Valuation: the transaction valued Maziv at about R36bn pre-money (R29.8bn after the pre-implementation dividend) and the combined entity at over R47bn (Daily Investor; BusinessTech).
SEACOM
Description: subsea fibre-optic cable system serving Southern and East Africa. Provides international wholesale bandwidth and enterprise connectivity.
Industrial
Air Products South Africa (50%)
Description: joint venture with Air Products & Chemicals Inc. (US). Produces oxygen, nitrogen, argon, hydrogen and CO₂.
Pricing model: pipeline/onsite supply contracts and bulk/cylinder sales.
Performance: H1 FY2026 earnings +11% on volumes and margins.
TotalEnergies Marketing South Africa (24.9%)
Description: fuel and lubricants marketing and retail network.
FY2026: contribution rose R424m. This includes a once-off Transnet pipeline cost refund (Remgro's share R218m) and positive stock revaluations. Results were partly offset by refinery supply constraints.
FY2025: contribution fell R359m on negative stock revaluations.
Wispeco (100%)
Description: aluminium extrusions manufacturer and distributor for the building, engineering and durables sectors.
FY2025 revenue: R3,909m.
Other platforms
Media & sport: eMedia (e.tv, eNCA, Openview) unbundled on 29 September 2025. Remaining sport interests include Blue Bulls rugby, Stellenbosch FC and the Stellenbosch Academy of Sport (Daily Investor, Apr 2026).
Diversified investment vehicles: - Kagiso Tiso Holdings (43.5%): a black-owned investment holding company.
- Other vehicles with exposure to South Africa and China (Old Mutual Aperture, Mar 2026). Individual vehicles were not enumerated in the sources reviewed.
Financial Narrative
Primary sources: Remgro audited results SENS (FY2025: 23 Sep 2025; FY2026: 18 Sep 2026), Profile's Stock Exchange Handbook (2026 Issue 1), and S&P Global Market Intelligence standardised statements via StockAnalysis (updated 18 Sep 2026). S&P standardisation may differ slightly from company-presented line items. Where they differ, both are noted.
Company performance measures (management basis)
Notes:
FY2022–FY2023 INAV per share: are derived from the disclosed discount to INAV (39.0% and 40.8%, per the FY2023 AFS) and the closing share prices (Profile's Handbook).
FY2026 price and discount: are derived (S&P closing price; 1 − 197.00/305.80). The company-reported FY2026 discount was not available.
FY2022 HE growth: is taken from Profile's 106.0% HEPS growth; HE growth is derived from FY2021 HE of R2,885m.
FY2024 HE: Profile shows R5,646m, the FY2025 SENS shows R5,647m (rounding).
Adjusted HEPS: FY2026 is per the results presentation (Quartr).
INAV total growth including distributions: in FY2026 was 8.9%.
Income statement (IFRS, S&P standardised)
Margins (%)
Growth (derived):
-
Revenue CAGR FY2022→FY2026 ≈ 5.1%.
-
Headline earnings CAGR FY2022→FY2026 ≈ 17.6%.
-
HEPS CAGR FY2022→FY2026 ≈ 18.1%.
-
Ordinary DPS CAGR FY2022→FY2026 ≈ 41.1%.
Commentary: revenue.
-
Consolidated revenue is essentially flat (+0.3% in FY2025, +0.9% in FY2026).
-
The flatness reflects RCL's weak sugar business and price deflation in poultry inputs, offset by Rainbow volume growth.
-
The FY2022 drop reflects Distell's deconsolidation (FY2021 revenue R65.8bn).
-
Revenue is not a meaningful measure of Remgro's economic performance.
Commentary: margins.
-
Gross margin expanded to 39.9% in FY2026 and operating margin to 7.5%, from 5.0% in FY2022.
-
Drivers: Rainbow's recovery (lower feed costs, stronger rand) and cost discipline at RCL Groceries and Siqalo. Sugar margin compression was a partial offset.
Commentary: the headline-earnings vs IFRS divergence (the key FY2026 inflection).
-
HE rose 42.3% to R11.14bn, but IFRS EPS fell about 56.5% to R2.59.
-
The cause is Remgro's share of Mediclinic's FY2026 impairments of Hirslanden (Switzerland). Mediclinic recorded $1.24bn of impairments in its year to March 2026: $555m restructuring-related and $689m on Swiss assets.
-
This is why S&P shows a negative R1,771m equity-accounted line.
-
Impairments are excluded from HE under JSE headline earnings rules.
Once-offs: HE included about R1.02bn of material once-off items. Excluding these, HE grew 29.3% to R10.1bn. The largest disclosed once-off is the TotalEnergies Transnet pipeline refund (Remgro share R218m).
FY2024 trough: HE −15% and IFRS net income R1.24bn reflect Heineken Beverages losses and the impairment of the Distell/Heineken goodwill. A R3.88bn loss on investments is shown in S&P data.
Commentary: finance costs. Interest expense fell from R1.0bn (FY2023) to R0.39bn (FY2026) following redemption of preference shares. This was worth R403m to FY2025 HE.
Balance sheet
Source: S&P Global via StockAnalysis (18 Sep 2026). Short/long-term debt splits are derived by summing S&P components. Profile's Handbook shows FY2023 attributable equity of R115,267m vs S&P's R115,920m; the difference is a restatement or classification. "Cash at the centre" (company measure) was R20.4bn at 30 June 2026 (+143.6%) and R22.5bn post year-end. This differs from consolidated cash, which includes subsidiary cash.
Balance sheet commentary.
-
Remgro has de-geared decisively, from total debt of R15.6bn (FY2022) to R4.9bn (FY2026). The company is now in a R20.7bn consolidated net cash position.
-
The FY2026 jump in cash reflects four inflows:
-
FirstRand disposals (R8.47bn).
-
The BAT sale (R1.21bn).
-
The CIVH pre-implementation dividend.
-
Strong dividend receipts.
-
-
The decline in long-term investments (R89.6bn to R78.9bn) reflects:
-
Removal of the FirstRand fair-value stake.
-
The eMedia distribution.
-
Mediclinic's equity-accounted carrying value reduced by Swiss impairments.
-
-
After 1 July 2026, Remgro paid $947m (about R15.3bn) for MCSA and received a $130m distribution. Part of this was settled through restructuring mechanics (the "MCSA Loan" referenced in the SENS), so the net cash impact is not fully disclosed. Management nonetheless reported cash at the centre rising to R22.5bn post year-end. Readers should expect the FY2027 balance sheet to show MCSA consolidated (adding hospital assets, debt and goodwill).
Cash flow
Source: S&P Global via StockAnalysis. FY2026 OCF, capex, FCF and net borrowing are from the S&P statistics page (Oct 2026); FY2026 dividends paid and buybacks were not available in a verified annual statement. Company FCF at the centre FY2026 (R8.31bn, +105.6%) and adjusted per share (891c, +28.6%) are from Remgro's FY2026 results via Daily Investor and Quartr. FY2025 FCF-at-centre values are derived (8,310/2.056; 891/1.286).
Cash flow commentary.
Dividend receipts: these rose 104.4% in FY2026, including the once-off CIVH pre-implementation dividend.
-
R2.06bn (Daily Investor, FY2026 results article).
-
R2.66bn received on implementation (Business Day, interim results).
-
About R2.7bn (Old Mutual Aperture).
-
R3.06bn in total (Daily Investor, later article). The R2.66bn figure, attributed to the interim results, is the most specific. The R2.06bn may reflect the portion classified in FY2026 FCF after adjustments.
Dividend policy: management maintains an ordinary dividend cover of 1.5x adjusted free cash flow at the centre. FY2026 is consistent: 891c / 595c ≈ 1.50x.
Ratios
Source: S&P Global via StockAnalysis, and derived. The cash conversion cycle was not computed by the company or by S&P in the sources reviewed. Profile's Handbook reports differently defined ratios, e.g., FY2025 return on shareholders' funds 2.57% and current ratio 3.74.
Ratio commentary.
-
IFRS returns are structurally low and volatile for an investment holding company carrying equity-accounted stakes at cost plus retained earnings. They are not the right yardstick.
-
Better measures:
-
HE return on equity: rose from 5.0% (FY2024) to 9.3% (FY2026).
-
INAV per share total return including distributions: 8.9% in FY2026.
-
INAV per share CAGR FY2024→FY2026: about 10.4%.
-
Liquidity: exceptional, with a current ratio of 5.3x and net cash of about 4x EBITDA. This provides optionality for both reinvestment and distributions.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment revenue (ZAR Mn)
| Segment revenue (ZAR Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
RCL Foods (FY2022–FY2024 incl. Rainbow) | 32,201 | 37,783 | 40,511 | 26,494 | — |
Rainbow | — | — | — | 15,838 | — |
Capevin | -1 | 421 | 2,659 | 1,923 | — |
Siqalo Foods | 3,546 | 3,748 | 3,594 | 3,715 | — |
Wispeco | 3,598 | 3,813 | 3,759 | 3,909 | — |
Other segments | 74 | 77 | 90 | -111 | — |
Inter-segment eliminations | -163 | -167 | -189 | -262 | — |
Total consolidated revenue | 41,875 | 48,151 | 50,424 | 51,506 | 51,010 |
Segment Revenue
| Segment | FY2024→FY2025 growth % | FY2025 share of revenue % |
|---|---|---|
RCL Foods + Rainbow (combined, like-for-like) | 4.5 | 82.2 |
Capevin | -27.7 | 3.7 |
Siqalo Foods | 3.4 | 7.2 |
Wispeco | 4.0 | 7.6 |
Platform Details
| Platform | % of INAV (HY2026) | Key holdings |
|---|---|---|
Healthcare | 24.4 | Mediclinic |
Financial services | 20.6 | OUTsurance Group, Business Partners, minority listed stakes |
Consumer products | 15.5 | RCL Foods, Rainbow, Siqalo, Heineken Beverages, Capevin |
Infrastructure | 10.0 | CIVH (Maziv), SEACOM |
Industrial | 7.4 | Air Products SA, TotalEnergies SA, Wispeco |
Cash, other investments, diversified vehicles, central (derived residual) | 22.1 | Central cash R12bn at 31 Dec 2025 plus remaining FirstRand (sold Feb–Apr 2026), KTH and other |
Change in headline earnings contribution (ZAR Mn)
| Change in headline earnings contribution (ZAR Mn) | FY2025 | FY2026 |
|---|---|---|
Mediclinic | 362 | 1,370 |
Rainbow Chicken | 324 | 610 |
CIVH | — | 412 |
OUTsurance Group | 318 | 332 |
Heineken Beverages | 406 | 161 |
TotalEnergies SA | -359 | 424 |
RCL Foods | 264 | — |
Lower finance costs (preference share redemption) | 403 | — |
Key Financials and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Headline earnings (ZAR Mn) | 5,816 | 6,642 | 5,647 | 7,827 | 11,140 |
Headline earnings growth % | 101.6 | 14.2 | -15.0 | 38.6 | 42.3 |
HEPS (ZAR cents) | 1,031 | 1,180 | 1,018 | 1,409 | 2,003 |
HEPS growth % | 106.0 | 14.5 | -13.7 | 38.4 | 42.2 |
Adjusted HEPS excl. once-offs (ZAR cents) | — | — | — | — | 1,819 |
INAV per share (ZAR) | 208.7 | 248.4 | 251.01 | 292.34 | 305.80 |
INAV per share growth % | — | 19.0 | 1.0 | 16.5 | 4.6 |
Closing share price at 30 June (ZAR) | 127.32 | 147.05 | 136.09 | 158.20 | 197.00 |
Discount to INAV % | 39.0 | 40.8 | 45.8 | 45.9 | 35.6 |
Total INAV (ZAR Bn) | — | — | 139.3 | 162.5 | — |
Income statement (ZAR Mn)
| Income statement (ZAR Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue | 41,876 | 48,151 | 50,424 | 50,559 | 51,010 |
Revenue growth % | -36.4 | 15.0 | 4.7 | 0.3 | 0.9 |
Gross profit | 15,810 | 17,339 | 18,238 | 18,894 | 20,365 |
Operating income (EBIT) | 2,109 | 2,316 | 2,680 | 3,087 | 3,817 |
EBITDA | 4,382 | 4,203 | 3,664 | 4,191 | 4,981 |
Earnings from equity-accounted investments | 10,786 | 3,296 | 2,799 | 1,617 | -1,771 |
Interest expense | 887 | 1,002 | 933 | 503 | 387 |
Interest and investment income | 1,023 | 2,146 | 1,646 | 1,492 | 1,753 |
Pre-tax income | 13,584 | 6,535 | 2,230 | 4,143 | 3,002 |
Income tax | 757 | 832 | 948 | 957 | 1,170 |
Net income attributable to shareholders | 13,139 | 9,624 | 1,241 | 3,303 | 1,438 |
EPS basic (ZAR cents) | 2,328 | 1,710 | 224 | 595 | 259 |
EPS diluted (ZAR cents) | 2,313 | 1,696 | 218 | 586 | 252 |
Ordinary dividend per share (ZAR cents) | 150 | 240 | 264 | 344 | 595 |
Special dividend per share (ZAR cents) | 0 | 0 | 0 | 200 | 550 |
Margin (%)
| Margin (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin | 37.75 | 36.01 | 36.17 | 37.37 | 39.92 |
Operating (EBIT) margin | 5.04 | 4.81 | 5.32 | 6.11 | 7.48 |
EBITDA margin | 10.46 | 8.73 | 7.27 | 8.29 | 9.77 |
Net margin | 31.38 | 19.99 | 2.46 | 6.53 | 2.82 |
Effective tax rate | 5.57 | 12.73 | 42.51 | 23.10 | 38.97 |
Balance Sheet and Per-Share Data
| Balance sheet (ZAR Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets | 156,698 | 150,965 | 139,178 | 142,174 | 144,875 |
Cash and equivalents | 11,884 | 6,047 | 6,789 | 8,855 | 14,933 |
Cash and short-term investments | 17,584 | 10,629 | 9,488 | 12,231 | 25,636 |
Short-term debt (incl. current LTD and leases) | 2,928 | 6,627 | 4,671 | 346 | 341 |
Long-term debt (incl. leases) | 12,703 | 6,327 | 1,952 | 4,482 | 4,566 |
Total debt | 15,631 | 12,954 | 6,623 | 4,828 | 4,907 |
Net debt (negative = net cash) | -1,953 | 2,325 | -2,865 | -7,403 | -20,729 |
Long-term investments (associates, JVs, other) | 71,663 | 99,159 | 90,085 | 89,562 | 78,913 |
Goodwill | 7,970 | 7,084 | 7,073 | 6,307 | 6,189 |
Other intangibles | 12,305 | 3,581 | 3,554 | 3,594 | 3,241 |
Goodwill and intangibles | 20,275 | 10,665 | 10,627 | 9,901 | 9,430 |
Inventory | 13,568 | 7,832 | 8,497 | 9,341 | 10,280 |
Total current assets | 45,709 | 30,351 | 26,815 | 29,911 | 43,281 |
Total current liabilities | 19,690 | 16,737 | 12,984 | 7,876 | 8,169 |
Working capital | 26,019 | 13,614 | 13,831 | 22,035 | 35,112 |
Shareholders' equity attributable | 98,443 | 115,920 | 112,117 | 117,039 | 120,291 |
Minority interest | 17,437 | 6,521 | 7,047 | 6,840 | 6,833 |
Total equity | 115,880 | 122,441 | 119,164 | 123,879 | 127,124 |
Book value per share (ZAR) | 174.52 | 207.51 | 202.04 | 210.55 | 216.07 |
Cash flow (ZAR Mn)
| Cash flow (ZAR Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow | 7,806 | 2,480 | 4,772 | 6,860 | 9,688 |
Capital expenditure | 3,272 | 3,266 | 1,948 | 1,972 | 2,070 |
Free cash flow (consolidated) | 4,534 | -786 | 2,824 | 4,888 | 7,618 |
Common dividends paid | 721 | 1,075 | 1,637 | 1,883 | — |
Share repurchases | 137 | 830 | 726 | 0 | — |
Net debt issued (repaid) | -1,686 | -1,947 | -5,664 | -2,287 | 57 |
Free cash flow at the centre (company measure) | — | — | — | 4,042 | 8,310 |
Adjusted FCF at the centre per share (ZAR cents) | — | — | — | 693 | 891 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE % (IFRS, S&P) | 11.69 | 4.79 | 1.06 | 2.62 | 1.46 |
ROE on headline earnings % (derived) | 5.9 | 5.7 | 5.0 | 6.7 | 9.3 |
ROA % (S&P) | 0.89 | 0.94 | 1.16 | 1.37 | 1.66 |
ROIC % (S&P) | 1.80 | 1.69 | 1.28 | 2.04 | 2.09 |
Current ratio (x) | 2.32 | 1.81 | 2.07 | 3.80 | 5.30 |
Debt to equity (x) | 0.14 | 0.11 | 0.06 | 0.04 | 0.04 |
Net debt to EBITDA (x) | -0.45 | 0.55 | -0.78 | -1.77 | -4.16 |
Interest coverage EBIT/interest (x, derived) | 2.38 | 2.31 | 2.87 | 6.14 | 9.86 |
Asset turnover (x) | 0.28 | 0.31 | 0.35 | 0.36 | 0.36 |
Inventory turnover (x) | 1.99 | 2.88 | 3.94 | 3.55 | 3.12 |
Mediclinic Region Details
| Mediclinic region | Revenue growth % | EBITDA margin % | Margin change (bp) |
|---|---|---|---|
Switzerland (Hirslanden; exited 1 Jul 2026) | 0 | — | 170 |
Southern Africa (now 100% Remgro) | 8 | 18.5 | 70 |
Middle East (50/50 with IHL) | 11 | 16.9 | 270 |
Group | 10 | 15.5 | 170 |
Share price (ZAR)
| Share price (ZAR) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Closing price at 30 June | 127.32 | 147.05 | 136.09 | 158.20 | 197.00 |
Financial-year high | 151.76 | 148.40 | 164.01 | 164.99 | — |
Financial-year low | 105.13 | 122.07 | 116.00 | 129.28 | — |
Return period (price only, approximate)
| Return period (price only, approximate) | Return % | Basis |
|---|---|---|
1 year (to 7 Oct 2026) | 16.4 | S&P 52-week change |
Year to date 2026 (to 18 Sep 2026) | 12.3 | Business Day |
About 3 years (30 Jun 2023 → 14 Oct 2026) | 41.1 | Derived: 207.48 / 147.05 |
About 5 years (30 Jun 2021 → 14 Oct 2026) | 84.7 | Derived: 207.48 / 112.31 |
Valuation Multiples
| Multiple | Remgro | Notes |
|---|---|---|
P/E on IFRS EPS | about 80x | Distorted by Mediclinic impairments (S&P: 81.1x) |
P/HEPS | about 10.4x | Derived: 207.48 / 20.03 |
P/adjusted HEPS | about 11.4x | Derived: 207.48 / 18.19 |
Forward P/E (S&P consensus) | 10.25x | S&P |
P/INAV | about 0.68x | Derived |
P/B (IFRS) | 0.89x | S&P |
EV/EBITDA (consolidated) | 29.0x | S&P; not meaningful for a holding company |
EV/Sales | 1.94x | S&P |
Ordinary dividend yield | about 2.9% | Derived: 595c / R207.48 |
Total yield incl. special | about 5.5% | Derived: 1,145c / R207.48 |
Dividend (ZAR cents per share)
| Dividend (ZAR cents per share) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Interim ordinary | — | 80 | 80 | 96 | 173 |
Final ordinary | — | 160 | 184 | 248 | 422 |
Total ordinary | 150 | 240 | 264 | 344 | 595 |
Special | 0 | 0 | 0 | 200 | 550 |
Total declared | 150 | 240 | 264 | 544 | 1,145 |
Share repurchases (ZAR Mn)
| Share repurchases (ZAR Mn) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Buybacks | 137 | 830 | 726 | 0 |
Capital Markets
| Item | Status |
|---|---|
Moody's / S&P / Fitch issuer rating | No public rating identified in sources reviewed |
National-scale ratings (e.g., GCR) | Not identified |
Debt profile | Total consolidated debt R4.9bn at 30 Jun 2026: short-term R0.34bn, long-term R4.57bn incl. leases. Largely subsidiary-level borrowings (RCL, Rainbow, Wispeco) |
Centre-level debt | Preference shares redeemed (FY2024–FY2025), lowering finance costs by R403m in FY2025 |
Analyst Conclusions
Management guidance (FY2026 results presentation, as summarised by Quartr)
-
Focus shifts from portfolio transformation to value compounding, using a strong balance sheet and a simplified portfolio.
-
Continued disciplined capital allocation, prioritising performance, growth opportunities and sustainability.
-
AI identified as a lever to accelerate strategic execution.
-
Dividend cover guidance maintained at 1.5x adjusted FCF.
-
Positioned for resilience and optionality amid macro and geopolitical volatility.
-
No quantitative FY2027 earnings guidance disclosed.
Consensus expectations
-
S&P consensus (2 analysts): forward P/E about 10.3x, implying forward EPS (headline-type) of roughly R19–R20, i.e., flat versus FY2026 reported HEPS.
-
3-year EPS growth forecast: about 5.7% per year.
-
Market expectations therefore embed normalisation: the FY2026 once-offs (about R1.02bn) are not expected to repeat.
Bull case
-
Clean, cash-rich, control-oriented portfolio. About R22.5bn of central cash (about R40 per share) plus 100% of MCSA, 57% of CIVH and a 50% joint venture in Air Products. Disciplined deployment or further distributions could compress the discount further from about 32%.
-
Underlying earnings compounding. Adjusted HEPS grew 29% in FY2026. Fibre (Vumatel +15%), Middle East healthcare (+11% revenue, +270bp margin) and OUTsurance provide structural growth, while Rainbow and Heineken Beverages recover.
-
Value marks from transactions. Vodacom's entry implied a Maziv pre-money value of about R30–36bn with an option for more. The Hirslanden/MCSA swap gave Remgro a $130m equalisation payment and exit from impaired Swiss assets.
Bear case
-
High-water-mark earnings. About R1.02bn of once-offs (TotalEnergies refund, CIVH-related items) and a lower FirstRand dividend base mean FY2027 HE could stall or fall. Higher interest income on cash is temporary if cash is deployed or distributed.
-
Structural discount persists. Dual-class control (over 40% of votes), opaque unlisted valuations and South African country risk may keep the discount at 30–40%. INAV per share grew only 4.6% in FY2026 despite record earnings.
-
Concentrated South African risk after the Swiss exit. MCSA (NHI risk), RCL sugar (import exposure), poultry cycles and weak industrial output (August 2026 mining −12.7%) increase dependence on a low-growth domestic economy. The Middle East conflict adds risk to the remaining international healthcare leg.
Key catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing | What to watch |
|---|---|---|
| Ex-dividend for the 422c final and 550c special | 21 Oct 2026 | Share-price adjustment; reinvestment flows |
| FY2026 Integrated Annual Report and remuneration report | Oct–Nov 2026 | Updated stake percentages, INAV breakdown, risk register, pay outcomes |
| AGM | Nov 2026 (unconfirmed) | Votes on remuneration policy; buyback authority |
| First consolidated MCSA numbers | H1 FY2027 results (Mar 2027) | Margin trajectory (18.5% H1 FY2026 base), debt consolidated, purchase-price allocation |
| Deployment of R22.5bn cash | Ongoing | Acquisitions vs buybacks vs special dividends |
| RCL Foods corporate action | Speculative | Any minority offer, sugar separation or Siqalo combination (unconfirmed) |
| Maziv performance and Vodacom option (+4.95%) | Ongoing | Vumatel growth, capex, option exercise as a valuation signal |
| Middle East situation | Ongoing | Mediclinic ME admissions and margins |
| Heineken Beverages trajectory | Ongoing | Sustained profitability; valuation recovery |
| Discount to INAV | Ongoing | Narrowing below about 30% would signal re-rating |
Concluding analyst verdict
Remgro has largely completed the most consequential portfolio transformation in its 26-year listed history.
Exits: FirstRand, BAT, Grindrod, eMedia and the impaired Swiss hospital business.
Additions: full control of Mediclinic Southern Africa; Maziv co-control with Vodacom, which validated value and supplied capital.
Balance sheet: net cash of over R20bn.
The FY2026 numbers show that the restructuring is now flowing into earnings and cash. Headline earnings reached a record R11.14bn (+42%), adjusted HEPS rose 29%, FCF at the centre more than doubled, and over 90% of INAV reported earnings growth. The dividend policy of 1.5x adjusted FCF cover makes shareholder returns explicit and rules-based. The 550c special dividend shows a willingness to return realisation proceeds rather than hoard them.
The investment case is not without tension:
-
FY2026 benefited from roughly R1bn of non-recurring items, so FY2027 faces a demanding base.
-
INAV per share grew only 4.6% while earnings rose more than 40%. This suggests either conservative unlisted valuations or offsetting declines (OUTsurance's share price, RCL), and it underlines how much of the value now sits in assets marked by directors rather than by markets.
-
The portfolio is now more concentrated in South Africa just as domestic growth is soft and healthcare policy remains uncertain.
-
Governance concentration through class B voting shares remains a structural cap on the multiple.
On balance, at about 0.68x INAV, about 10x headline earnings and a total declared dividend yield of about 5.5%, the market is pricing Remgro as a well-capitalised but slow-compounding South African conglomerate. The asymmetric upside lies in what management does with R22.5bn of cash and whether MCSA and Maziv can compound at double-digit rates under direct control. The downside is cushioned by cash representing roughly 19% of market capitalisation.
Verdict: fundamentally improved and de-risked, with further discount narrowing contingent on capital-allocation execution over the next 12–24 months. Investors should anchor on adjusted HEPS (R18.19), adjusted FCF per share (891c) and INAV per share (R305.80) rather than IFRS EPS.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / appointment | Background |
|---|---|---|---|
Jannie Durand | Chief Executive Officer, executive director | CEO since 7 May 2012; previously Chief Investment Officer | Succeeded the late Thys Visser. Earlier: VenFin leadership and Remgro investment roles. Education reported as BAcc Hons (Stellenbosch) and MPhil (Oxford) |
Neville Williams | Chief Financial Officer, executive director | — | Chartered accountant background |
Mariza Lubbe | Chief Compliance and Operations Officer, executive director | Long-serving executive | — |
Carel Vosloo | Chief Investment Officer; alternate executive director to the CEO | Joined Remgro March 2022 as Investment Executive; alternate director and Management Board member since 5 Apr 2024 | RMB (2004–2022), including co-head of Corporate Finance and co-head of Investment Banking; RMB Executive member 2014–2022. BAcc Hons (Stellenbosch), MCom Tax (Wits), CA(SA), CFA |
Pieter Neethling | Alternate director | — | — |
Luché Joubert | Company Secretary | From 1 Nov 2024 | — |
Board of Directors
| Director | Role | Classification | Notes |
|---|---|---|---|
Johann Rupert | Chair | Non-executive (not independent; controlling family) | Also chairs Richemont. Born 1950 (age 76; public record) |
Sonja De Bruyn | Deputy Chair and Lead Independent Director | Independent non-executive | Deputy Chair from 1 Jul 2025; Audit & Risk Committee member |
Jannie Durand | CEO | Executive | — |
Neville Williams | CFO | Executive | — |
Mariza Lubbe | Chief Compliance & Operations Officer | Executive | — |
Anton Rupert | Director | Non-executive | Appointed Nov 2018; Rupert family |
Josua Malherbe | Director | Non-executive | Former co-deputy chair (appointed 2014) |
Gerrit Nieuwoudt | Director | Non-executive (listed as "ne" in Profile 2026) | Audit & Risk Committee member (2024 proposal) |
Phumzile (P J) Moleketi | Director | Independent non-executive | Social & Ethics and Sustainability Committee from Sep 2024 |
Murphy Morobe | Director | Independent non-executive | Remuneration & Nomination Committee from 15 Jul 2025 |
K S (Sello) Rantloane | Director | Independent non-executive | Audit & Risk Committee member |
Christine Ramon | Director | Independent non-executive | Appointed 27 Nov 2025. Former AngloGold Ashanti CFO (8 years, incl. a year as interim CEO); NED of Vodafone plc and Clicks Group |
Carel Vosloo | Alternate to CEO | Executive alternate | — |
Pieter Neethling | Alternate | — | — |
Major Shareholders
| Shareholder | Stake | Date | Source |
|---|---|---|---|
Rupert family (via unlisted class B shares) | Over 40% of voting rights | 2026 | BusinessTech, Mar 2026 |
Public Investment Corporation (Government Employees Pension Fund) | 16.04% of ordinary shares | 30 Jun 2025 | Profile's Handbook 2026 |
Ninety One SA (clients) | 5.10% (Jun 2025); 5.0156% after crossing the 5% threshold on 17 Aug 2026 | 2025–2026 | Profile's Handbook; BusinessTech, Aug 2026 |
Fairtree Asset Management | 5.01% | 30 Jun 2025 | Profile's Handbook 2026 |
Institutions (aggregate) | 49.50% | Oct 2026 | S&P Global via StockAnalysis |
Insiders (aggregate, ex-B-share voting) | 1.65% | Oct 2026 | S&P Global via StockAnalysis |
Competitive Landscape
Key Competitors
| Peer | Type | Relative positioning vs Remgro |
|---|---|---|
Reinet Investments | Rupert-family international investment holding (Luxembourg; JSE-listed) | Sister vehicle; international private equity and credit; not a direct competitor for South African assets |
Hosken Consolidated Investments (HCI) | South African diversified holding company (media, gaming, energy, property) | Smaller; overlaps in media (eMedia, now unbundled by Remgro) |
African Rainbow Capital Investments (ARC) | B-BBEE investment holding company (financial services, diversified) | Smaller; trades at a deep NAV discount; competes for financial services and telecom deals |
Brait | Investment holding (Virgin Active, Premier Group, New Look) | Smaller and more leveraged; overlaps in consumer goods (Premier vs RCL) |
PSG Group (unbundled 2023) / Zeder | Former Stellenbosch peer holding companies, now largely unbundled | Illustrates the "unbundle to close the discount" route |
Sabvest Capital | Small diversified holding company | Much smaller; similar long-term-holder model |
Global/local private equity (Ethos, Old Mutual Alternatives, international PE) | Private capital | Compete for control positions in South African unlisted assets |
Competitor Detail
| Remgro investee | Segment | Named direct competitors |
|---|---|---|
Mediclinic Southern Africa | Private hospitals | Netcare, Life Healthcare, National Hospital Network members |
Rainbow Chicken | Poultry | Astral Foods, Quantum Foods, Sovereign Foods, imports |
RCL Foods (Groceries/Baking) | Packaged foods and bread | Tiger Brands, Premier Group (Brait), Pioneer Foods (PepsiCo), Libstar |
RCL Foods (Sugar) | Sugar | Tongaat Hulett, Illovo Sugar, imports |
Siqalo Foods | Spreads and oils | Willowton Group, Upfield, private-label brands |
Heineken Beverages | Beer, cider, spirits | South African Breweries (AB InBev), Diageo |
Maziv (Vumatel/DFA) | Fibre | Openserve (Telkom), Frogfoot, MetroFibre, Liquid Intelligent Technologies |
OUTsurance | Short-term insurance | Santam, Hollard, Discovery Insure, King Price, Old Mutual Insure |
Air Products SA | Industrial gases | Afrox (Linde) |
TotalEnergies SA | Fuel retail | Vivo Energy (Engen/Shell), Astron Energy, Sasol, BP |
Wispeco | Aluminium extrusions | Hulamin Extrusions, imports |
Competitor Detail — Latest fiscal year
| Metric | Remgro |
|---|---|
Latest fiscal year | FY Jun 2026 |
Revenue (ZAR Bn) | 51.0 |
Revenue growth % | 0.9 |
Headline earnings growth % | 42.3 |
EBITDA margin % (consolidated) | 9.8 |
Discount to NAV % | c.32 (Oct 2026, derived) |
Recent Developments
Date discrepancy flag: * FY2026 results publication is reported as Friday 18 September 2026 (Daily Investor, Business Day, BusinessTech). Pre-results coverage and S&P list 21 September as the earnings date, and Quartr lists the event on 23 September. Most likely, the SENS was released on 18 September and the presentation was held on 21 September.



